Read More

Orphazyme Announced Goldman Sachs Aggregate Holding of Shares and Financial Instruments in the Company Increased to 5.8% as of June 16, 2021 and aas Reduced to Less than 5% as of June 17, 2021

Orphazyme A/S (NASDAQ: ORPH) ("the Company"), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notifications pursuant to Section 38 of the Danish Capital Markets Act from The Goldman Sachs Group, Inc., that as of June 16, 2021,

ORPH